SCHEMBL8302809

SCHEMBL8302809

O=C(O)c1cccc(Cl)c1OCCOC1CCCCO1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
KDM4C Q9H3R0 1/20 0.40
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
CCNA1 P78396 1/20 0.38
CDK5 Q00535 1/20 0.38
CDK5R1 Q15078 1/20 0.38
F2 P00734 1/20 0.37
F9 P00740 1/20 0.37
F10 P00742 1/20 0.37
CFD P00746 1/20 0.37
PLG P00747 1/20 0.37
PLAU P00749 1/20 0.37
PLAT P00750 1/20 0.37
F11 P03951 1/20 0.37
KLKB1 P03952 1/20 0.37
F7 P08709 1/20 0.37
CREBBP Q92793 2/20 0.37
EP300 Q09472 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8301720 0.89 MEN1 (0.44) KMT2AMEN1KDM4CCCNA2CDK2
SCHEMBL8297699 0.88 MEN1 (0.43) KMT2AMEN1KDM4CCCNA2CDK2
SCHEMBL8296603 0.86 MEN1 (0.54) KMT2AMEN1KDM4CF2F9
SCHEMBL8296596 0.86 MEN1 (0.51) KMT2AMEN1KDM4CCREBBPEP300
SCHEMBL21818634 0.84 KMT2A (0.51) KMT2AMEN1KDM4CCREBBPEP300
SCHEMBL871773 0.81 KMT2A (0.55) KMT2AMEN1KDM4CCREBBPHTT
SCHEMBL8296601 0.77 MEN1 (0.54) KMT2AMEN1KDM4CCREBBPTSHR
SCHEMBL8296597 0.77 MEN1 (0.51) KMT2AMEN1KDM4CCREBBPTSHR
SCHEMBL9335071 0.76 KMT2A (0.61) KMT2AMEN1KDM4CHTTL3MBTL1
SCHEMBL16036295 0.76 MEN1 (0.49) KMT2AMEN1KDM4CCREBBPEP300

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090035313-A1 Compounds PFIZER INC. 2009-02-05 US disclosed
US-20090035313-A1 Compounds PFIZER INC. 2009-02-05 US disclosed
EP-1651641-B1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LTD (GB) 2007-05-23 EP disclosed
EP-1651640-B1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LTD (GB) 2007-02-14 EP disclosed
WO-2005009995-A1 NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS PFIZER LIMITED (GB) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035313-A1 Compounds NQO1, NAMPT, NNT KMT2A 2721/4885MEN1 532/4885KDM4C 2548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.